Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
HER2-enriched breast cancers within the HER2-positive subtype are addicted to the HER2 pathway. Here, the authors analyse gene expression before, during, and after treatment with anti-HER2-based therapies in the phase II PAMELA clinical trial, finding phenotypic changes induced by treatment.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-14111-3 |